TNFRSF8 expression

P1, N=57, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Apr 2029 --> Apr 2026 | Trial primary completion date: Apr 2028 --> Apr 2026

Early biopsy, immunophenotypic analysis, and clinicopathologic correlation are essential to guide appropriate management in atypical or treatment-resistant lesions. Rather than demonstrating a novel association with HS, this report emphasizes diagnostic and classification challenges at the interface between primary cutaneous and systemic ALCL, which are of direct relevance to cutaneous pathologists.

Localized radiotherapy was then administered, which resulted in progressive improvement of the lesion from the first sessions, with tumor volume reduction, decreased exudate, and partial re-epithelialization of the ulcerated bed. This case highlights the role of localized radiotherapy as an effective palliative and disease-controlling modality for cutaneous CD30+ T-cell lymphoma, particularly in symptomatic or treatment-refractory lesions.

P1, N=42, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting | Trial completion date: Jul 2028 --> Jul 2029 | Trial primary completion date: Jan 2027 --> Jan 2028

P2, N=170, Suspended, Alliance for Clinical Trials in Oncology | Trial completion date: Jun 2026 --> May 2027 | Trial primary completion date: Jun 2026 --> May 2027

The sensitivity of CyTOF enabled discrimination of uptake between cell models even at low metal-to-antibody stoichiometric ratios. It also revealed intercellular variability in uptake that can only be captured with single-cell methods. Overall, we showed that CyTOF is a robust, high-throughput, multiplexed approach for characterizing the cellular uptake of stable radiopharmaceutical surrogates at single-cell resolution, paving the way for future studies.

Published cases suggest that IN-TSCT may exhibit aggressive clinical behavior, including metastatic spread in a subset of patients; however, the total number of reported cases remains very limited, and the true metastatic risk and prognostic spectrum have not yet been clearly defined. This review synthesizes the available literature to provide a comprehensive clinicopathologic and molecular overview of this emerging tumor entity.

CD123 is frequently expressed on neoplastic MCs in SM by flow cytometry, across all subtypes. These findings support further investigation of CD123 as a therapeutic target and warrant correlation with IHC and clinical outcomes in larger cohorts.

This case demonstrates that IVLBCL can present with diffuse interstitial lung disease and generalized lymphadenopathy, expanding its recognized phenotypic spectrum. It may represent a variant with CD30-mediated nodal homing and immune activation.

Immunohistochemistry for ALK and HHV8 should be included in the diagnostic panel. Importantly, CD30 and EBER positivity do not exclude ALK + LBCL.

P1, N=18, Recruiting, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

RNA sequencing confirmed higher CD30 (TNFRSF8) gene expression levels in high-risk tumours (logFC = 2.3182; FDR = 0.0405). These findings suggest that CD30 is a promising biomarker with potential prognostic value in canine cutaneous MCTs.